Observational study of safety and tolerability of Levemir FlexPen (insulin detemir) in the treatment of type 1 and type 2 diabetes mellitus

Trial Profile

Observational study of safety and tolerability of Levemir FlexPen (insulin detemir) in the treatment of type 1 and type 2 diabetes mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2014

At a glance

  • Drugs Insulin detemir (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 16 Oct 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 16 Oct 2009 Actual patient number (3299) added as reported by ClinicalTrials.gov.
    • 16 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top